| Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial A Grothey, E Van Cutsem, A Sobrero, S Siena, A Falcone, M Ychou, ... The Lancet 381 (9863), 303-312, 2013 | 3042 | 2013 |
| Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial WTA Van Der Graaf, JY Blay, SP Chawla, DW Kim, B Bui-Nguyen, ... The Lancet 379 (9829), 1879-1886, 2012 | 2206 | 2012 |
| Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation H Gelderblom, J Verweij, K Nooter, A Sparreboom European journal of cancer 37 (13), 1590-1598, 2001 | 2115 | 2001 |
| Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised … GD Demetri, P Reichardt, YK Kang, JY Blay, P Rutkowski, H Gelderblom, ... The Lancet 381 (9863), 295-302, 2013 | 1474 | 2013 |
| Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial I Judson, J Verweij, H Gelderblom, JT Hartmann, P Schöffski, JY Blay, ... The lancet oncology 15 (4), 415-423, 2014 | 996 | 2014 |
| Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, N Abecassis, S Bauer, R Biagini, S Bielack, S Bonvalot, ... Annals of Oncology 29, iv51-iv67, 2018 | 942 | 2018 |
| Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, N Abecassis, S Bauer, R Biagini, S Bielack, S Bonvalot, ... Annals of Oncology 29, iv68-iv78, 2018 | 914* | 2018 |
| Combination chemotherapy in advanced adrenocortical carcinoma M Fassnacht, M Terzolo, B Allolio, E Baudin, H Haak, A Berruti, S Welin, ... New England Journal of Medicine 366 (23), 2189-2197, 2012 | 888 | 2012 |
| The clinical approach towards chondrosarcoma H Gelderblom, PCW Hogendoorn, SD Dijkstra, CS Van Rijswijk, AD Krol, ... The oncologist 13 (3), 320-329, 2008 | 825 | 2008 |
| Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial P Schöffski, S Chawla, RG Maki, A Italiano, H Gelderblom, E Choy, ... The Lancet 387 (10028), 1629-1637, 2016 | 771 | 2016 |
| Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up ESMO/European Sarcoma Network Working Group Annals of oncology: official journal of the European Society for Medical …, 2014 | 704 | 2014 |
| Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, JY Blay, A Bertuzzi, S Bielack, B Bjerkehagen, S Bonvalot, ... | 604* | 2014 |
| Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, S Bielack, N Abecassis, HT Aro, S Bauer, R Biagini, ... Annals of Oncology 29, iv79-iv95, 2018 | 522 | 2018 |
| Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? JK Anninga, H Gelderblom, M Fiocco, JR Kroep, AHM Taminiau, ... European journal of cancer 47 (16), 2431-2445, 2011 | 516 | 2011 |
| Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ A Gronchi, AB Miah, AP Dei Tos, N Abecassis, J Bajpai, S Bauer, ... Annals of Oncology 32 (11), 1348-1365, 2021 | 476 | 2021 |
| Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label … NM Marina, S Smeland, SS Bielack, M Bernstein, G Jovic, MD Krailo, ... The Lancet Oncology 17 (10), 1396-1408, 2016 | 471 | 2016 |
| Clinical pharmacokinetics of tyrosine kinase inhibitors NP van Erp, H Gelderblom, HJ Guchelaar Cancer treatment reviews 35 (8), 692-706, 2009 | 470 | 2009 |
| Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort S Smeland, SS Bielack, J Whelan, M Bernstein, P Hogendoorn, MD Krailo, ... European journal of cancer 109, 36-50, 2019 | 456 | 2019 |
| Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications A Sparreboom, L Van Zuylen, E Brouwer, WJ Loos, P De Bruijn, ... Cancer research 59 (7), 1454-1457, 1999 | 434 | 1999 |
| Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up A Berruti, E Baudin, H Gelderblom, HR Haak, F Porpiglia, M Fassnacht, ... Annals of oncology 23, vii131-vii138, 2012 | 413 | 2012 |
